956440-82-7 Usage
Uses
Used in Pharmaceutical Research:
(5-AMINO-3-METHYL-PYRAZOL-1-YL)-ACETIC ACID ETHYL ESTER is used as a reagent in pharmaceutical research for the development of new drugs. Its unique structure and functional groups allow for the creation of novel compounds with potential therapeutic properties, contributing to the advancement of medical treatments.
Used in Agrochemical Development:
In the agrochemical industry, (5-AMINO-3-METHYL-PYRAZOL-1-YL)-ACETIC ACID ETHYL ESTER is used as a reagent for the synthesis of various agrochemical products. Its properties make it suitable for the development of new compounds with potential applications in pest control, crop protection, and other agricultural areas.
Used in Chemical Synthesis:
(5-AMINO-3-METHYL-PYRAZOL-1-YL)-ACETIC ACID ETHYL ESTER is also utilized as a reagent in general chemical synthesis. Its functional groups and chemical properties enable the creation of a wide range of organic compounds, which can be applied in various industries beyond pharmaceuticals and agrochemicals, such as materials science, dyes, and coatings.
Check Digit Verification of cas no
The CAS Registry Mumber 956440-82-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,6,4,4 and 0 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 956440-82:
(8*9)+(7*5)+(6*6)+(5*4)+(4*4)+(3*0)+(2*8)+(1*2)=197
197 % 10 = 7
So 956440-82-7 is a valid CAS Registry Number.
956440-82-7Relevant academic research and scientific papers
Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M
Kim, Ho Shin,Hammill, Jared T.,Scott, Daniel C.,Chen, Yizhe,Rice, Amy L.,Pistel, William,Singh, Bhuvanesh,Schulman, Brenda A.,Guy, R. Kiplin
supporting information, p. 5850 - 5862 (2021/05/29)
The cullin-RING ubiquitin ligases (CRLs) are ubiquitin E3 enzymes that play a key role in controlling proteasomal degradation and are activated by neddylation. We previously reported inhibitors that target CRL activation by disrupting the interaction of defective in cullin neddylation 1 (DCN1), a CRL neddylation co-E3, and UBE2M, a neddylation E2. Our first-generation inhibitors possessed poor oral bioavailability and fairly rapid clearance that hindered the study of acute inhibition of DCN-controlled CRL activity in vivo. Herein, we report studies to improve the pharmacokinetic performance of the pyrazolo-pyridone inhibitors. The current best inhibitor, 40, inhibits the interaction of DCN1 and UBE2M, blocks NEDD8 transfer in biochemical assays, thermally stabilizes cellular DCN1, and inhibits anchorage-independent growth in a DCN1 amplified squamous cell carcinoma cell line. Additionally, we demonstrate that a single oral 50 mg/kg dose sustains plasma exposures above the biochemical IC90 for 24 h in mice.
